ARTICLE | Clinical News
ISIS 2302: Phase II
October 15, 2001 7:00 AM UTC
ISIP said ISIS 2302 improved symptoms of active distal UC in a European placebo-controlled, dose-escalation Phase II trial in 40 patients. Patients receiving an enema formulation of the compound had a...